Kyverna Therapeutics Inc (NASDAQ: KYTX) kicked off on Friday, up 6.19% from the previous trading day, before settling in for the closing price of $3.39. Over the past 52 weeks, KYTX has traded in a range of $3.15-$35.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -37.90% over the last five years. While this was happening, its average annual earnings per share was recorded 96.32%. With a float of $18.72 million, this company’s outstanding shares have now reached $43.17 million.
The firm has a total of 96 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Kyverna Therapeutics Inc (KYTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Kyverna Therapeutics Inc is 56.65%, while institutional ownership is 32.17%. The most recent insider transaction that took place on Feb 12 ’24, was worth 5,568,992. In this transaction 10% Owner of this company bought 253,136 shares at a rate of $22.00, taking the stock ownership to the 252,553 shares. Before that another transaction happened on Feb 12 ’24, when Company’s 10% Owner bought 450,000 for $22.00, making the entire transaction worth $9,900,000. This insider now owns 3,163,868 shares in total.
Kyverna Therapeutics Inc (KYTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 96.32% per share during the next fiscal year.
Kyverna Therapeutics Inc (NASDAQ: KYTX) Trading Performance Indicators
Take a look at Kyverna Therapeutics Inc’s (KYTX) current performance indicators. Last quarter, stock had a quick ratio of 10.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.07, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.72 in one year’s time.
Technical Analysis of Kyverna Therapeutics Inc (KYTX)
Analysing the last 5-days average volume posted by the [Kyverna Therapeutics Inc, KYTX], we can find that recorded value of 0.81 million was better than the volume posted last year of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 35.98%. Additionally, its Average True Range was 0.34.
During the past 100 days, Kyverna Therapeutics Inc’s (KYTX) raw stochastic average was set at 8.77%, which indicates a significant decrease from 40.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.00% in the past 14 days, which was lower than the 84.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.26, while its 200-day Moving Average is $8.40. Now, the first resistance to watch is $3.92. This is followed by the second major resistance level at $4.25. The third major resistance level sits at $4.54. If the price goes on to break the first support level at $3.30, it is likely to go to the next support level at $3.01. Now, if the price goes above the second support level, the third support stands at $2.68.
Kyverna Therapeutics Inc (NASDAQ: KYTX) Key Stats
The company with the Market Capitalisation of 155.42 million has total of 43,172K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -60,370 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -34,490 K.
